20/20 Gene Systems

  • The company offers diagnostic tests to screen for tumor biomarkers and rapid antibody tests for COVID-19 in a Clinical Laboratory Improvement Amendments (CLIA)-approved laboratory
  • Proprietary data analytics algorithms integrate clinical data from subjects together with tumor biomarker data to a...

This research is archived and therefore no longer available. For further assistance please contact your Customer Success Manager or email ClientEngagementTeam@luxresearchinc.com. Thank you!

Related Research

SOPHiA Genetics

Company Snapshot | July 19, 2021

The company was started by CEO Jurgi Camblong, Lars Steinmetz, and Pierre Hutter in 2011; it has raised $250 million in total funding, with $110 million from a Series F round in 2020. The company is a developer of SOPHiA DDM (Data‑Driven Medicine), an AI‑enabled SaaS platform that analyzes genomic, ... To read more, click here.


Company Profile | July 27, 2021

Develops Bisu Body Coach, a platform for frequent at‑home lab testing and wellness tracking; the core of its technology is a microfluidic test stick system that utilizes optical spectroscopy to measure biomarkers The test stick is capable of having 11 different reagents on its microfluidic chip... Not part of subscription

Viz.ai receives European CE mark for its AI-based stroke detection platform

News Commentary | July 12, 2021

Viz.ai's AI platform works by identifying large vessel occlusions (LVOs) based on medical imaging. Last year, the company released a study that demonstrated a 96% sensitivity and 94% specificity at detecting LVOs in 2,544 patients across multiple scanner types. The CE mark allows Viz.ai to market ... Not part of subscription